J&J takes on Novartis’ Cosentyx with head-to-head psoriasis trial

Remicade (infliximab) facing increasing competition from biosimilars. ... TNF inhibitor Remicade’s sales fell by around 15% in the first nine months of the year to $4.1bn, mainly due to price reductions, while Tremfya sales were $369m globally

ViiV’s two-drug HIV combo backed by CHMP

Sandoz’ Zessly, a biosimilar of J&J’s Remicade (infliximab) for the treatment of rheumatoid arthritis, Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis and psoriasis.

Mundipharma adds breast cancer biosimilar to its portfolio with Celltrion deal

This will be the third biosimilar Mundipharma and Celltrion has launched in the EU, following Remsima (infliximab) and Truxima (rituximab), biosimilars of Johnson and Johnson’s Remicade and Roche’s MabThera.

The good, the bad and the ugly

Another top-selling drug also experienced decline for similar reasons: J&J’s Remicade - still in the top 10 best-selling products of 2017 - fell back by 7.5% due to

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]